V ascular endothelial growth factor (VEGF) is a key protein regulating angiogenesis under physiological and pathological conditions. [1] [2] [3] [4] [5] VEGF is a homodimeric glycoprotein identifiable as 5 isoforms (206, 189, 165, 145 , and 121 amino acids), generated by alternative splicing from a single gene. 6 The human VEGF 165 form was shown to be angiogenic and is secreted from various cells as a soluble factor. 7, 8 Local administration of VEGF 165 enhanced reendothelialization in denuded arteries in vivo 9 and increased the formation of new blood vessels in ischemic myocardium and limbs. 10 -12 Vegf 165 gene transfer to vascular tissue was shown to improve blood flow in ischemic limbs and myocardium. [13] [14] [15] The use of Vegf 165 gene transfer to induce therapeutic angiogenesis is currently the focus of several animal and human studies. 16 -19 Therapeutic angiogenesis has the potential to improve symptoms in patients with ischemic syndromes who are not candidates for mechanical revascularization procedures. 15,20 -23 VEGF 165 binds to the high-affinity tyrosine kinase receptors VEGF-R1 (flt-1) and VEGF-R2 (KDR/flk-1), which are expressed almost exclusively in endothelial cells (ECs). 24 -26 In addition, VEGF 165 binds to the recently identified neuropilin-1 and neuropilin-2 receptors, which are also VEGF 165 receptors expressed by ECs. 27 Activation of the kinase insert domain-containing receptor (KDR) represents a major step in VEGF 165 -initiated angiogenesis. The expression of this receptor is temporally and spatially correlated with VEGF expression during development. Studies using a dominant-negative mutation of flk-1 (the mouse homologue of the KDR receptor) have shown that this receptor plays a major role as a regulator of tumor angiogenesis. 28, 29 Both VEGF 165 and KDR expression are upregulated by hypoxemia. 30 -33 To explore the changes in receptor expression induced by VEGF 165 overexpression in vascular cells, we developed a recombinant adenoviral vector encoding VEGF 165 and infected human vascular cells with the recombinant adenovirus. The present study examined VEGF 165 binding to the KDR receptors in primary human ECs and smooth muscle cells (SMCs) after infection by recombinant adenoviral vector encoding VEGF 165 .
Methods

Preparation of Adenoviral Vectors
The recombinant adenoviral vectors expressing the human VEGF 165 (rAdVEGF) or the bacterial ␤-galactosidase (rAdlacZ) genes were constructed by cloning and a homologous recombination procedure in the 293 cell line. 34 A 600-bp BamHI fragment containing the human VEGF 165 cDNA, including the signal sequence for secretion (gift of Dr J. Abraham, Scios Nova, Mountain View, Calif) and the 3700-bp HindIII-BamHI fragment containing the bacterial ␤-galactosidase gene were inserted separately into pCA3 plasmid, under the control of the constitutive cytomegalovirus (CMV) immediate early promoter. This expression plasmid also contained the left arm (16%) of the Ad5 genome, with a deletion in the E1 region into which hCMV was inserted. 35 The pCA3 plasmid containing the VEGF 165 or the ␤-galactosidase genes was cotransfected with the pJM17 plasmid 36 into 293 cells. Homologous recombination between the expression plasmid and pJM17 after transfection replaced the E1 region with the expression cassette from the pCA3 plasmid. Plaque formation occurred between 2 and 4 weeks after cotransfection. Individual plaques were isolated, and the viral extracts were amplified by infection of 293 cells. The titer of each viral stock was determined by plaque assay in 293 cells, and the titers ranged at Ϸ10 10 pfu/mL. The presence of the cDNA insert was confirmed by X-gal staining of infected cells for ␤-galactosidase expression and Western analysis of growth medium for VEGF secretion.
Cell Culture
ECs were isolated from human saphenous veins (HSVECs) and cultured on gelatin-coated dishes in M-199 medium (Beit Haemek) supplemented with 20% human serum, 100 g/mL heparin (Sigma), and 2 ng/mL basic fibroblast growth factor. Human ECs were identified by immunohistochemistry using anti-von Willebrand factor-specific antibodies (Zymed). SMCs were cultured by explant outgrowth from human saphenous veins (HSVSMCs) and left internal mammary arteries (HLSMCs). Cells were cultured in DMEM (Beit Haemek) supplemented with 10% FCS (Beit Haemek). SMCs were identified by antibodies specific to ␣-smooth muscle actin (Zymed). The 293 cell line was cultured in DMEM containing 10% FCS.
Cell Proliferation Assay
ECs and SMCs (passages 5 to 11) were seeded 24 hours before adenoviral infection at 30% confluence (5ϫ10 4 cells/35 mm and 1ϫ10 5 cells/35 mm, respectively) in medium containing 2% serum and 2 ng/mL basic fibroblast growth factor. The cells were infected (10 3 pfu/cell) in serum-free medium with rAdVEGF or rAdlacZ as a control adenoviral vector. Two additional control groups were used: uninfected cells, which were grown in the presence of 2 or 10 ng/mL baculovirus-derived recombinant human VEGF 165 (added twice daily), 37 and a control group of untreated cells. After 90 minutes of exposure to adenoviral vectors at 37°C, serum-containing medium was added, and 16 to 18 hours later, the medium was substituted with M199 containing 7% human serum (HSVECs) or DMEM with 2% FCS (HSVSMCs, HLSMCs). Two, 5, 7, and 12 days later, the cells were trypsinized and counted in triplicate by hemacytometer. Cell proliferation was also measured quantitatively by bromodeoxyuridine (BrdU) immunohistochemistry assay according to the manufacturer's recommendation (Zymed).
Northern Analysis for KDR RNA
Total RNA (10 to 20 g) isolated 38 from HSVECs was fractionated on a 1.2% formaldehyde-agarose gel and transferred to nytrane filters (MSI). The probe, a 791-bp fragment containing the KDR gene, was labeled with 32 P by random priming. 39 After hybridization, filters were washed and autoradiographed on Kodak BS-XAR film at Ϫ80°C. The radioactivity intensity was measured after the films had been photographed and analyzed with an Electrophoresis Documentation and Analysis System (EDAS 12, Kodak). Differences in RNA loading amounts were calculated according to the 28S band intensity detected in the ethidium bromide-stained gel.
Western Blot Analysis for VEGF 165
ECs and SMCs were infected as described above. At days 2, 5, 7, and 12 after infection, the supernatants were collected to test for VEGF 165 secretion. Secreted VEGF 165 was extracted from supernatant proteins through a heparin-sepharose column (Pharmacia). Extracted samples were loaded on 12.5% SDS-polyacrylamide gel under reducing conditions and electroblotted onto nitrocellulose (Schleicher & Schuell). A 1:700 dilution of rabbit polyclonal antibody against the amino-terminal epitope (1 to 20 amino acids) of VEGF 165 (Santa Cruz) was used. After exposure to a peroxidase-conjugate secondary antibody (Sigma), blots were developed with ECL reagents (Sigma) and autoradiographed.
S-Methionine Labeling and KDR Immunoprecipitation
Three days after infection of ECs by adenoviral vectors, the growth medium was replaced with 2 mL DMEM, high glucose, without methionine. After 2 hours of incubation at 37°C, the medium was replaced by 2.5 mL DMEM (without methionine) and 10 g/mL 35 S-methionine. After overnight incubation, the cells were lysed with 1 mL lysis buffer containing 1% nonident P-40, 0.5% deoxycholate, and protease inhibitors. The lysates were centrifuged briefly to remove insoluble debris, and 45 L of anti-KDR agarose-conjugated antibody (SC-504AC, Santa Cruz) was incubated for 6 hours at room temperature. After 3 washes with cold PBS (5 minutes each), the KDR receptors were eluted by 3 minutes of boiling in sample buffer and separated on a 6% SDS-polyacrylamide gel.
Iodination of VEGF 165 and Receptor Cross-Linking
Iodination of 5 g of human recombinant VEGF 165 was performed by the chloramine T method. Free iodine was separated from 125 I-VEGF 165 by heparin-sepharose affinity chromatography. The specific activity of 125 I-VEGF 165 was 0.5 to 1.5ϫ10 5 cpm/ng. 26 HSVECs and HSVSMCs were grown in 60-or 35-mm dishes. The cells were washed with cold PBS, and the binding of 125 I-labeled VEGF 165 was carried out in binding buffer containing DMEM, 25 mmol/L HEPES (pH 7.4), 1 g/mL heparin, and 0.1% gelatin for 2 hours at 4°C. In cross-linking experiments, the washed cell layer was incubated with disuccinimidyl suberate, followed by SDSpolyacrylamide gel electrophoresis, chromatography of cell lysates, and autoradiography. 26 The gels were stained with Coomassie blue to assess the amounts of loaded protein. The intensity of the bands was evaluated by densitometry (EDAS 120, Kodak) and adjusted to protein amounts detected by scanning of the stained gels. The effect of suramin on 125 I-VEGF 165 binding to the receptors was examined by addition of 0.2 mmol/L suramin (Sigma) to the growth medium after adenoviral infection.
Results
Effect of rAdVEGF on EC and SMC Proliferation
EC infection with rAdVEGF led to a significant increase in EC number compared with the control groups (rAdlacZinfected and uninfected cells) (PϽ0.0001 for days 2, 5, 7, and 12 by ANOVA). The enhanced EC proliferation was similar to the mitogenic effect observed by addition of 2 ng/mL recombinant VEGF 165 to uninfected EC growth medium (Figure 1) . Similar findings were observed with BrdU incorporation for identification of DNA-synthesizing cells. Enhanced BrdU incorporation rate (up to 5-fold) compared with the control group was detected 5 days after Vegf 165 gene transfer by recombinant adenovirus (data not shown). In contrast, overexpression of VEGF 165 after rAdVEGF infection in SMCs did not confer a growth advantage over the control groups of rAdlacZ-infected and uninfected cells and had no effect on BrdU incorporation.
VEGF 165 Expression by Infected ECs and SMCs
Secreted VEGF was detected in conditioned medium samples collected from both human ECs and SMCs infected by rAdVEGF. Two specific bands were detected, 19 and 22 kDa in size, which represent the glycosylated and nonglycosylated forms of VEGF 165 monomer (Figure 2 ). These bands exhibited a pattern similar to that of the purified recombinant VEGF 165 protein, which was used as positive control. In contrast, no VEGF 165 production was detected in control cells infected by rAdlacZ or uninfected cells. The production of VEGF 165 protein was detected 2 days after infection and persisted up to 12 days after infection ( Figure 2 ).
I-VEGF 165 Binding to KDR Receptor
KDR receptor expression was examined by affinity crosslinking analysis at 2 different time points (2 and 5 days) after adenovirus infection of HSVECs. The 125 I-VEGF 165 binding pattern of HSVECs was similar to the recognized pattern found in human umbilical vein ECs (HUVECs). 26 Two specific major bands were detected: the upper band (Ϸ220 kDa), which represents the KDR receptor, and the lower band, which was recently identified as the neuropilin receptor ( Figure 3 ). 27 rAdVEGF infection of ECs led to enhanced 125 I-VEGF 165 binding to its specific receptors. A 3-fold increase in VEGF 165 binding to the KDR receptor was detected 2 days after infection ( Figure 3A) , and further augmentation (6-fold) at day 5, compared with the control groups ( Figure  3B ). Similar results were obtained by the addition of conditioned medium collected from rAdVEGF-infected ECs as well as addition of 10 ng/mL recombinant VEGF protein to noninfected cells (6.4-and 7.2-fold increase in KDR binding, respectively, Figure 3B, lanes 4 and 6) . Addition of a lower concentration of recombinant VEGF (2 ng/mL) to noninfected ECs, however, did not induce increased KDR binding ( Figure 3B, lane 4) . In contrast to rAdVEGF-infected cells, 125 I-VEGF 165 binding was not changed by infection with the adenoviral control vector (rAdlacZ).
In accordance with the increased KDR binding, an increased binding of 125 I-VEGF 165 to the neuropilins was observed (4-to 5-fold increase). Both neuropilin receptors (1 and 2) specifically bind the VEGF 165 isomer. Because there is a size similarity between neuropilin 1 and 2, we assume that the increased binding observed relates to both receptors.
The binding and cross-linking assay was performed separately with 2 different concentrations of labeled protein, 1 and 5 ng/mL of 125 I-VEGF 165 ( Figure 3A) . A concentration of 1 ng/mL 125 I-VEGF 165 was found to saturate KDR receptors in both control groups (cells infected with rAdlacZ and uninfected cells), because binding intensity did not increase with higher concentration (5 ng/mL) of labeled protein. Nonetheless, rAdVEGF-infected cells exhibited a 3-fold increased binding in the presence of 5 ng/mL 125 I-VEGF 165 compared with binding at a concentration of 1 ng/mL. To prove specificity of 125 I-VEGF 165 binding, 1 g/mL unlabeled VEGF was added to the assay. An excess of VEGF eliminated binding because of competition of the unlabeled ligand ( Figure 3A) . These phenomena indicate that KDR binding of VEGF 165 was enhanced in ECs overexpressing VEGF 165 after gene transfer.
To test whether ECs overexpressing VEGF are activated by an autocrine mechanism, we used suramin, a polyanionic drug known to inhibit growth factor-receptor interaction, to limit the external effect of VEGF. Addition of 0.2 mmol/L suramin to EC growth medium after infection by rAdVEGF led to a moderate (40%) decrease in 125 I-VEGF binding intensity (data not shown). Suramin inhibited VEGF binding both to KDR receptors and to neuropilins. Furthermore, addition of suramin to ECs that were supplemented with 2 ng/mL exogenous VEGF 165 eliminated the basal levels of VEGF binding (data not shown). Because the suramin concentration used was subcytotoxic to the endothelial cells, no higher concentrations were tested. These results imply that an autocrine mechanism is responsible for the increased proliferation observed in cells overexpressing VEGF. Because a high concentration of VEGF 165 would be needed in vivo to induce KDR upregulation for induction of the angiogenic switch and because supplemented VEGF is subjected to degradation and dilution in tissue fluids, we conclude that an autocrine activation after gene transfer is superior to protein supplementation.
KDR Expression by Infected ECs
The effect of VEGF 165 overexpression by rAdVEGF-infected endothelial cells on KDR gene expression was examined by Northern analysis. Levels of KDR mRNA expressed by untreated HSVECs at baseline remained unchanged after rAdVEGF infection and the addition of 10 g/mL recombinant VEGF protein (Figure 4) . To examine the effect of VEGF overexpression on KDR protein expression, an immunoprecipitation assay was performed. A significant increase in KDR protein levels was detected in rAdVEGF-infected ECs ( Figure 5, lane 3) , in uninfected cells supplemented with exogenous recombinant VEGF protein (lane 4), and in uninfected ECs supplemented with rAdVEGF-infected EC conditioned medium (lane 5). From these experiments, we concluded that increased expression of KDR was due to posttranscriptional regulation.
Discussion
The major findings of this study were that VEGF overexpression by ECs resulted in autocrine-mediated enhanced proliferation, augmented KDR expression, and increased VEGF 165 binding to the KDR and neuropilin receptors. Upregulation of flk1/KDR (VEGFR-2) receptor levels was reported in other experimental systems. Shen et al 40 showed that VEGF induced upregulation of KDR mRNA and protein expression directly in bovine adrenal cortex endothelial cells via the activation of the receptor's tyrosine kinase in vitro. Induction of receptor gene transcription was observed in this study, whereas in our experiments, changes were detected in KDR protein levels only. Upregulation of VEGFR-2 protein levels was implicated in mouse cerebral slice cell culture by recombinant VEGF 165 ; this effect was inhibited by preincubation with a neutralizing anti-VEGF 165 antibody. 41 VEGFR-2 upregulation was also demonstrated in avian embryo after transduction by retroviral vectors by 2 groups: in the developing chick limb bud after recombinant quail vegf 122 gene transfer and in the chorioallantoic membrane by the addition of recombinant human VEGF 121 . 42, 43 These reports focused on induction of VEGFR-2 protein expression. Unlike the previous reports, Brogi et al 32 reported no effect on KDR expression in HUVECs by high concentrations of VEGF (100 ng/mL). The conflicting findings of all the cited reports may reflect differences in experimental models, endothelial cell phenotype, and activity of various VEGF preparations.
The exact role of neuropilins in angiogenesis is still unclear. Early data show that semaphorines bind to neuropilins; semaphorine 3 was shown to inhibit EC migration. 44 Neuropilin-1 mutant mice were shown to exhibit various types of vascular defects, indicating a crucial role for this receptor in the developing embryo 45 ; still, the physiological consequences of VEGF binding to neuropilin receptors are yet to be fully explored. Our findings may provide a clue to the role of neuropilin, because binding of VEGF was increased in parallel to the increase in KDR binding, but our data cannot determine whether these changes have a synergistic or inhibitory effect. The role of other isoforms of VEGF in KDR activation and binding to neuropilins can be inferred from differences in their properties. 46 VEGF 121 is a secreted isoform that lacks the heparin-binding domain; it does not bind to neuropilins. 47 VEGF 189 is a nonsecreted isoform and therefore is not expected to produce an autocrine effect in ECs.
The sensitization phenomenon of ECs overexpressing VEGF can be ascribed to the fact that human ECs do not produce VEGF 165 under physiological conditions. Upregulation of the KDR receptor due to VEGF overexpression represents a positive feedback mechanism that is physiologically important in the process of angiogenesis.
Therapeutic Implications
Upregulation of KDR receptor binding in infected cells may represent a potential advantage of gene transfer over protein treatment. Although direct application of VEGF 165 protein may be sufficient to induce angiogenesis in animal models and ischemic tissues in humans, its short half-life in the serum and the high concentration needed for upregulation of its receptor may hamper its in vivo efficiency. 48 The addition of suramin blocked KDR binding in ECs supplemented with 2 ng/mL VEGF, whereas only a moderate reduction was observed in rAdVEGF-infected ECs. The increased binding in our studies may explain the therapeutic effects observed after vegf gene transfer by plasmid vector despite the low efficiency of plasmid gene transfer in vivo. 10, 15 Because KDR upregulation is triggered by VEGF, a process requiring several days, it is reasonable to assume that by the time KDR is upregulated, the concentration of supplemented VEGF will be very low. Gene transfer confers the advantage of an autocrine, prolonged effect on the cell and should produce increased protein expression through a longer time period.
